<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="979">
  <stage>Registered</stage>
  <submitdate>4/01/2006</submitdate>
  <approvaldate>4/01/2006</approvaldate>
  <actrnumber>ACTRN12606000010594</actrnumber>
  <trial_identification>
    <studytitle>Phase II Study to Determine Predictive Markers of Response to MDX-010 (BMS-734016)</studytitle>
    <scientifictitle>Phase II Study to Determine Predictive Markers of Response to MDX-010 (BMS-734016) in Patients with Unresectable Stage III or IV Malignant Melanoma</scientifictitle>
    <utrn />
    <trialacronym>CA184-004</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Unresectable Stage III or IV Malignant Melanoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Malignant melanoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Dose Comparison of MDX-010 (BMS-734016).  Treatment up to week 10 and beyond depending upon response.</interventions>
    <comparator />
    <control>Dose comparison</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To identify candidate markers predictive of response and/or serious toxicity to MDX-010 (BMS-734016). </outcome>
      <timepoint> Tumour response measured starting at week 12 through week 24. Those continuing on therapy after week 24 have tumour responses evaluated every 3 months.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety &amp; tumour response.</outcome>
      <timepoint>Safety evaluated on a continuous and ongoing basis.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Histologic or cytologic diagnosis of unresectable Stage III or IV malignant melanoma (excluding ocular melanoma). A pre- and post-treatment fresh core or excision tumour biopsy must be provided.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>No exclusion criteria</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation to numbered containers.</concealment>
    <sequence>Interactive voice response system (IVRS) to assign patient to dose group based on randomisation schedule computer generated and maintained by sponsor. Randomisation using a permuted block procedure and stratification.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>15/03/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>80</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bristol-Myers Squibb Pty Ltd.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Bristol-Myers Squibb Pty Ltd</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>None</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Mr Richard Wykes</name>
      <address>Department of Medical Oncology
Royal Prince Alfred Hospital
Missenden Road
Camperdown NSW 2050</address>
      <phone>+61 2 95156902</phone>
      <fax>+61 2 95155063</fax>
      <email>richard.wykes@email.cs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Mr Richard Wykes</name>
      <address>Department of Medical Oncology
Royal Prince Alfred Hospital
Missenden Road
Camperdown NSW 2050</address>
      <phone>+61 2 95156902</phone>
      <fax>+61 2 95155063</fax>
      <email>richard.wykes@email.cs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>